Ancillary Product Patents to Extend Biologic Patent Life
JAMA · 05.12.2023 · 330 (21) · 2117
DOI: 10.1001/jama.2023.19547 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, erschienen am 05.12.2023. Verfasst von Rachel Goode und 2 weiteren Autor:innen. Beteiligte Einrichtung: Fresenius Kabi USA, Washington, DC. Hauptthemen laut MEDLINE: Biological Products, Biosimilar Pharmaceuticals, Patents as Topic. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
This study examines all patents associated with biologic litigation to understand how manufacturers use ancillary product patents to delay biosimilar market entry.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Fresenius Kabi USA, Washington, DC.
- Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts.
- West Virginia University College of Law, Morgantown.
Förderung
- NHLBI NIH HHS
Zitieren
APA
Goode, R., Feldman, W. B., & Tu, S. S. (2023). Ancillary Product Patents to Extend Biologic Patent Life. JAMA, 330(21), 2117. https://doi.org/10.1001/jama.2023.19547
Vancouver
Goode R, Feldman WB, Tu SS. Ancillary Product Patents to Extend Biologic Patent Life. JAMA. 2023;330(21):2117. doi:10.1001/jama.2023.19547
BibTeX
@article{Goode2023,
author = {Goode, Rachel and Feldman, William B and Tu, S Sean},
title = {Ancillary Product Patents to Extend Biologic Patent Life},
journal = {JAMA},
year = {2023},
volume = {330},
number = {21},
pages = {2117},
doi = {10.1001/jama.2023.19547}
}
EUVIMED